There are no generic Letairis (ambrisentan) products available at this time, as this medication is protected from generic competition by patents. After the first patent expires in December 2014, however, companies may be able to manufacture a generic version of this drug. Although ambrisentan is sometimes referred to as the generic name for Letairis, it is not a generic version of the drug.
Letairis® (ambrisentan) is a prescription medication used to treat the symptoms of pulmonary arterial hypertension, which is high blood pressure in the arteries of the lungs. It belongs to a group of medicines known as endothelin receptor antagonists.
Letairis is made by Gilead Sciences, Inc. It is currently protected by patents that prevent any generic Letairis from being manufactured in the United States.
The first patent for Letairis is set to expire in December 2014. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Letairis uses. Once the patent expires, there may be several companies that manufacture a generic Letairis drug.
No -- ambrisentan is the active ingredient in Letairis, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.